Short summary

Chemotherapy (FOLFIRINOX) followed by local therapy

(Resection, radiotherapy and/or IRE- irreversibel electo-poration) in patients with locally advanced pancreatic cancer (LAPC)

---

Rationale

---

Description of the cohort

Patients with locally advanced pancreatic cancer (LAPC). Patients are not primary resectable.

Data and biological material

Blood for tumormarkers every 8.th week

Questionaires (EORTC QLQ-PAN26)

Primary endpoint :

2 year survival for all patients starting chemotherapy 
Secondary endpoints:Quality of Life (EORTC QLQ-PAN26)PFSOSResponse rate (RECIST v1.1)Histological tumor regression (TRG)Adverse events grade 2-5 (NCI-CTCAE 4.0)Surgical complications, including IRE (Clavien)Number of patients with progression during chemotherapyNumber of patients with R0 resectionEvaluation of biomarkers 

Collaborating researchers and departments

Department of Oncology, Odense University Hospital

• Per Pfeiffer

Herlev

• Benny Vittrup Jensen

Aalborg

• Mette Yilmaz

Aarhus

• Morten Ladekarl

Stockholm

• Lars Lundell